Lupin Limited has informed the Exchange regarding a press release dated May 07, 2026, titled "Lupin FY2026 and Q4 FY2026 Results".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited reported strong full-year FY2026 results with sales up 23.9% to INR 2,74,875 Mn and PAT surging 62% to INR 53,555 Mn. EBITDA margin expanded significantly by 890 basis points to 33.6%, driven by robust performance in the U.S. market (up 46% for full year) and overall margin improvement. Q4 FY2026 was particularly strong with sales of INR 73,919 Mn (up 32.9% YoY) and PAT of INR 14,687 Mn (up 87.7% YoY). The company received 3 ANDA approvals during the quarter and has 151 generic products in the U.S. market. Exceptional items of INR 5,579 Mn (net) were recorded for the year. The Board recommended a dividend of 900%.
The results demonstrate strong operational performance with margin expansion and robust profit growth, indicating improved profitability and market position, particularly in the U.S. business. The strong PAT growth and cash generation (net debt of INR -46,358 Mn) are positive for shareholders.